AM Technology’s Post

🚀 Discover Innovative Drug Discovery Approach! Optimizing molecules for drug discovery is often a tedious and costly process. However, by implementing automation and miniaturization directly into biological assays, we can accelerate synthesis, save expensive reagents, and eliminate the need for extensive single-compound purification and handling. This innovative approach is commonly known as plate-based chemistry or direct-to-biology. In addition to classical small molecules, this method has been successfully applied to new modalities like PROTACs. At the upcoming EFMC-ISMC 2024, where we will showcase a proof-of-principle case study demonstrating automated reaction miniaturization of amide couplings, followed by direct biological readouts of unpurified reaction mixtures. 🌐Curious about the details? Visit our poster and schedule a meeting with our team for an in-depth discussion -> https://lnkd.in/excR7WYi #PlateBasedChemistry #LifeScienceChemistry #DrugDiscovery #EFMCISMC2024 #NUVISAN #ScienceCRO

🌟 What's shaping the future of drug discovery? 🌟  Discover the latest trends in medicinal chemistry, from PROTACs and targeted protein degradation to the rise of green fluoro chemistry. Molport highlighted the key innovations driving the next wave of therapeutic breakthroughs.  🔗 Dive deeper into these trends in our latest blog post.  https://lnkd.in/d-nbsJxh  #Molport #EFMC #ISMC #Innovation #DrugDiscovery #MedicinalChemistry #ChemicalResearch  

*Molecules of the Month - July Edition* This month, our MotM focuses on Target Protein Degradation and some of the medicinal chemistry approaches that are applied within this area of drug discovery. Read on to find out how LCC's proprietary linkers, virtual libraries and parallel synthesis capabilities can help accelerate you drug discovery efforts. 👇 #TargetProteinDegradation #Linkers #VirtualLibraries #DrugDiscovery

Covalent drug discovery is at our core. Speak to the Domainex team if you are attending or contact me to find out more! 1. Covalent fragments and screening 2. Peptide mapping 3. GSH reactivity screening 4. kinact/ki determination 5. Rapid hit expansion using Direct-to-Biology 6. H2L compound optimisation 7. Lead optimisation

New modalities, such as molecular glues, require robust screening strategies to identify and develop the most promising candidates. Affinity Selection Mass Spectrometry (ASMS) is a versatile and cost-effective high-throughput screening technique used in drug discovery. The ASMS platform at WuXi Biology is backed by a library of over 270,000 small molecules and offers customized screening services. The platform utilizes automated workflows, high-resolution mass spectrometry, and comprehensive validation through functional crossover studies. Importantly, dissociation constant (Kd) values are provided to accurately assess small molecule-protein binding affinity, ensuring precise ligand-binding measurements. Click this link 👇 to read our article: https://lnkd.in/gAFSQDJG #Biotech #DrugDiscovery #ASMS #MolecularGlues #HRMS #AffinitySelection

🔺46% compounds in the Enamine REAL Space October Update: 70 billion of accessible, drug-like molecules!   Enamine Ltd.'s REAL Space has once again made a significant leap in Chemical Space expansion, exceeding 70 billion tangible, on-demand compounds in the October 2024 update. This increase from 48 billion has never happened in such a dimension before and further strengthens one of the largest commercially available compound collections for drug discovery.   With 167 reactions and 170,202 reagents/building blocks, researchers can now explore an even wider Chemical Space using infiniSee.   Learn more about this update: https://lnkd.in/eGDxQdhV

As a pioneer in DNA-encoded chemical libraries (DEL)—and now a leader in integrated drug discovery supporting programs from target evaluation to hit ID and to candidate nomination, we are excited to share this article we helped review from Drug Hunter! DEL screens, as explained in the article, is a much more cost-effective complement to traditional high-throughput screening. One can assess billions of compounds for binding affinity at picomolar concentrations, while using just milligrams of targets of interest. - 1-million compound HTS library costs: $0.4-2 billion - 800-million compound DEL costs $150,000 With thoughtful experimental design, one can perform multiple selection experiments in parallel, investigating mechanism of actions (e.g. agonist, antagonist, allosteric), reducing off-target binding, and identifying selective hits that demonstrate competition with known inhibitors. Find out how our DEL screening strategies help different partners achieve their program goals: https://lnkd.in/et8iYZ_c

🚀 Join Us for an Exciting Online Seminar on November 26th! 🚀 Are you passionate about drug discovery and development? Don't miss our upcoming seminar on "In-House Crystallography Applied to Drug Discovery and Development"! 🔬 Key Topics: - Structure-Based Drug Design (SBDD): Learn how SBDD is revolutionizing the creation of effective drug substances. Imatinib (Gleevec) Development: 🏆 A Success Story 🏆 in SBDD: 1. Identification of the Target: Researchers identified the BCR-ABL fusion protein as the key driver of chronic myeloid leukemia (CML). This abnormal protein results from a chromosomal translocation known as the Philadelphia chromosome.  2. Structural Analysis: Using X-ray crystallography, scientists determined the three-dimensional structure of the BCR-ABL protein. This detailed structural 💠 information was crucial for understanding how the protein functions 💡 and how it could be inhibited. - Characterization of drug substances and drug products: Single Crystal X-Ray Diffraction (SC-XRD) provides uniquely detailed and unambiguous information on both the Active Pharmaceutical Ingredient (API) and solid forms (co-crystals, solvates or salts). 📅 Date: November 26th 🕒 Time: 9AM and 6PM CET 👨🔬 Speaker Bio: Dr. Vernon Smith, SC-XRD Business Development Manager at Bruker AXS, is a leading expert in single crystal X-ray diffraction (SC-XRD). Register now to gain insights from industry experts and elevate your knowledge in the field of drug discovery! 👉 https://lnkd.in/dWsCJcJ6 #DrugDiscovery #SBDD #Pharmaceuticals #Crystallography #DrugDevelopment #SolidForms #CoCrystals

We are proud to be part of #MC4DD - a New EU consortium focused on the discovery and application of macrocycles in drug discovery. In the frame of this collaboration, 8 universities and 6 industry partners join forces to advance the science of macrocycles as drugs. More information about MC4DD: www.MC4DD.com Together with Serhiy Ryabukhin (Enamine Ltd. and UORSY (Ukrorgsyntez Ltd.) Enamine Germany will focus on the design and production of specific building blocks for further application in macrocycle construction. See more about our capabilities in the area of macrocycle synthesis: https://lnkd.in/eHSZq-5x Exciting chemistry is ahead! #DrugDiscovery #Macrocycles #UORSY #OrganicChemistry #MedicinalChemistry

Tomorrow we will be presenting again at the meeting of the American Chemical Society, as Anna Petroff details how we are using #quantumcomputing today to generate protein-protein interaction inhibitors. Our Quantum-Aided Drug Design (QuADD) platform transforms molecular search into an optimization problem that can be run on today's #quantum annealers, finding relevant lead like molecules in a fraction of previous research timelines.